Table 2.

Baseline characteristics according to fibroblast growth factor 23 quartiles in the HALT-PKD Study B

Total, n=462FGF23 Quartiles, pg/mlP Value
Quartile 1 ≤50.3Quartile 2 =50.3–69.1Quartile 3 =69.1–92.5Quartile 4 >92.5
Age, yr, mean±SD49±849±849±849±849±80.78
Men, n (%)219 (47)52 (45)52 (45)60 (52)55 (48)0.70
White, n (%)431 (94)105 (91)110 (95)110 (95)106 (94)0.07
Systolic BP, mmHg, mean±SD129±15128±15128±12129±16131±150.38
Body mass index, kg/m2, mean±SD28±528±528±528±629±60.24
eGFR, ml/min per 1.73 m2, mean±SD48±1254±1151±1146±1041±10<0.001
Calcium, mg/dl, mean±SD9.4±0.59.3±0.69.4±0.49.5±0.49.4±0.60.11
Phosphate, mg/dl, mean±SD3.4±0.53.4±0.53.4±0.53.4±0.53.5±0.50.04
Urine albumin, mg/24 h, median (IQR)30 (17–75)25 (16–58)27 (16–58)31 (18–66)56 (19–138)0.01
PKD genotype 0, n (%)24 (6)6 (6)8 (7)5 (5)5 (5)0.90
PKD genotype 1, n (%)346 (81)85 (79)87 (80)88 (82)86 (85)
PKD genotype 2, n (%)55 (13)16 (15)14 (13)15 (14)10 (10)
  • Values are expressed as means±SD unless otherwise specified. FGF23, fibroblast growth factor 23; IQR, interquartile range. PKD, polycystic kidney disease.